A recent study showed some benefits to taking SGLT2 inhibitors to treat Type 2 diabetes.
The study compared certain SGLT2 inhibitors with other glucose-lowering drugs (oGLDs).
Results showed patients taking SGLT2 inhibitors to treat Type 2 diabetes were less likely to experience heart attack and stroke than patients using oGLDs.
The study also suggested SGLT2 inhibitors might offer Type 2 diabetes patients certain heart and cardiovascular benefits over oGLDs.
But the study results don’t tell consumers the whole story.
Here’s eight things consumers need to know about the latest SGLT2 inhibitor study:
Dr. Mikhail Kosiborod presented the study results this month at the 67th American College of Cardiology Scientific Sessions in Orlando. The Journal of the American College of Cardiology simultaneously published the study.
Drugwatch.com writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.
Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.
Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.(888) 645-1617